- Home
- NBY vs PCSA Comparison
NBY vs PCSA Comparison
Compare NBY & PCSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBY
- PCSA
- Stock Information
- Founded
- NBY 2000
- PCSA 2011
- Country
- NBY United States
- PCSA United States
- Employees
- NBY N/A
- PCSA N/A
- Industry
- NBY
- PCSA Biotechnology: Pharmaceutical Preparations
- Sector
- NBY
- PCSA Health Care
- Exchange
- NBY Nasdaq
- PCSA Nasdaq
- Market Cap
- NBY 3.5M
- PCSA 3.3M
- IPO Year
- NBY 2007
- PCSA N/A
- Fundamental
- Price
- NBY $0.62
- PCSA $0.20
- Analyst Decision
- NBY Strong Buy
- PCSA Strong Buy
- Analyst Count
- NBY 1
- PCSA 1
- Target Price
- NBY $0.85
- PCSA $2.00
- AVG Volume (30 Days)
- NBY 32.4K
- PCSA 44.0M
- Earning Date
- NBY 08-12-2025
- PCSA 08-12-2025
- Dividend Yield
- NBY N/A
- PCSA N/A
- EPS Growth
- NBY N/A
- PCSA N/A
- EPS
- NBY 0.57
- PCSA N/A
- Revenue
- NBY $9,781,000.00
- PCSA N/A
- Revenue This Year
- NBY $23.91
- PCSA N/A
- Revenue Next Year
- NBY $32.05
- PCSA N/A
- P/E Ratio
- NBY $1.34
- PCSA N/A
- Revenue Growth
- NBY 20.52
- PCSA N/A
- 52 Week Low
- NBY $0.36
- PCSA $0.15
- 52 Week High
- NBY $2.45
- PCSA $3.10
- Technical
- Relative Strength Index (RSI)
- NBY 56.70
- PCSA 40.59
- Support Level
- NBY $0.58
- PCSA $0.19
- Resistance Level
- NBY $0.64
- PCSA $0.33
- Average True Range (ATR)
- NBY 0.03
- PCSA 0.08
- MACD
- NBY 0.00
- PCSA -0.01
- Stochastic Oscillator
- NBY 62.38
- PCSA 2.17
About NBY NovaBay Pharmaceuticals Inc.
NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically-proven eyecare, wound care, and skin care products. Its product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is laboratory tested to have broad antimicrobial properties as it removes foreign material, including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available directly to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease.
About PCSA Processa Pharmaceuticals Inc.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).